Recent Advances in Antimultiple Myeloma Drug Development

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia and hypercalcemia have been the major serious sequelae that are inextricably linked with MM tumor progression. Despite the introduction of new treatment regimens, problematic neuropathy, thrombocytopenia, drug resistance and high MM relapse rates continue to plague the current therapies. New chemical agents are in development on the basis of understanding several signaling pathways and molecular mechanisms like tumor necrosis factor-α, proteasome, PI3K and MARKs. This review focuses on the most recent patents and clinical trials in the development of new medicine for the treatment of multiple myeloma. Furthermore, the important signaling pathways involved in the proliferation, survival and apoptosis of myeloma cells will be discussed.

The Progress of Research in Molecular Structure and Function of Histone Deacetylase 6

“…ACY-1215 can be used to treat multiple myeloma (MM). Combined with bortezomib, it can trigger synergistic anti MM effects and significantly reduce the viability of tumor cells [13]. The second one, Tubacin is a highly selective HDAC6 inhibitor with the chemical formula C 41 H 43 N 3 O 7 S and relative molecular weight 721.86 [14].…”

Fixed duration vs continuous therapy in multiple myeloma

“…Given these facts, it becomes clear that deepening our understanding of the pathophysiology of the disease, including the pathways driving clonal evolution, progression, and resistance, is key for the development of more rational therapies. 2 Because the outcome of research and the timelines of new advances are not predicable, we are left with optimizing treatment with the armamentarium available today. One of the options for gaining important improvements is to optimize treatment duration.…”